Fanconi anemia is an autosomal recessive disease characterized by a high risk of developing bone marrow (BM) failure and acute myelogenous leukemia. We studied growth of hematopoietic progenitor cells in long-term BM culture (LTBMC) We studied growth of BM cells in long-term cultures (LTBMC) in 8 persons with Fanconi anemia and BM failure. We found that differentiated myeloid cells were generated in these cultures and that cells able to initiate secondary LTBMC were present in the adherent layer harvested after 35 to 40 days. These data suggest that BM failure is not a consequence of absent hematopoietic precursor cells; other mechanisms must operate.
F
ANCON1 ANEMlA is an autosomal recessive disease characterized by congenital malformations and hematologic abnormalities, including bone marrow (BM) failure and leukemia. BM failure typically develops before 10 years of age, is progressive, and is sometimes associated with clonal cytogenetic abnormalities. Myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) may follow BM failure or develop without a detectable antecedent hematologic disorder. Actuarial risks of BM failure and leukemia (MDS and AML) by 40 years of age are 98% (95% confidence interval [CI] , 93% to 99%) and 52% (37% to 67%), respectively. ' The cause of BM failure in Fanconi anemia is unknown. One possibility is that it results from absent or defective he- We studied growth of BM cells in long-term cultures (LTBMC) in 8 persons with Fanconi anemia and BM failure. We found that differentiated myeloid cells were generated in these cultures and that cells able to initiate secondary LTBMC were present in the adherent layer harvested after 35 to 40 days. These data suggest that BM failure is not a consequence of absent hematopoietic precursor cells; other mechanisms must operate.
MATERIALS AND METHODS
Heparinized BM (0.5 to 4 mL) was obtained on one or more occasions from 8 persons with Fanconi anemia confirmed by diepoxybutane (DEB) testing8 and BM failure. Informed consent, approved by the institutional review board, was obtained from all subjects. Median age at study was 12 years (range, 0.5 to 32 years). Median duration of BM failure before study was 57 months (range. 1 to I58 months). Prior treatment of BM failure included androgens and transfusions. Cytogenetic studies were successful in 6 persons: 4 had 2 2 BM cells with the same abnormality (clonal cytogenetic abnormalities) on r> 1 occasion 2 of these had increased proportion of BM undifferentiated blasts at least in one study (Table l) .
BM spiculae were identified visually by decanting BM samples on the wall of a 50 mL plastic tube and removed using a Pasteur pipette. Buffy coat cells were obtained by centrifugation of the remaining BM at 1,200 rpm for 10 minutes. Spiculae and b u m coat cells were plated in 50-mL flasks in 6 mL MC Coys 5A medium containing 12.5% fetal calf serum (FCS), 12.5% horse serum, I % glutamine, 1% sodium pyruvate, 1% zntibiotics, I% nonessential amino acids, 1% vitamins, 1 % sodium bicarbonate, and mol/ L hydrocortisone (LTBMC medium). In some experiments, stem cell factor (SCF 10 ng/mL), interleukin-l ([L-l: 50 ng/mL), and IL-3 (51 ng/mL) were added to LTBMC medium alone or in combinatio 1s (SCF, IL-1, and IL-3 were gifts of Dr M.A.S. Moore). CUItures were incubated at 37°C in 5% O2 and 5% C02. After 4 to 7 days, nonadherent cells were centrifugated on a ficoll-hypaque p adient to remove red blood cells. Beginning on day 10, one-half of the culture supernatant was removed every 5 days and replaced by fresh LTBMC medium.. The nonadherent cells removed were counted and assessed for morphology, cytogenetis, andlor Colonyforming unit granulocyte-macrophage (CFU-GM). After 35 to 40 days, adhercnt layers were harvested by trypsinization and then incubated for 24 hours on a p1 wtic surface. Nonadherent cells were tested for their capability to initiate secondary LTBMC and for CFU-GM. 
RESULTS
BM samples contained 0.4 to 7 X lo6 cells/mL (median, I .6 X cells/mL). Fifty percent to 70% ofthese cells were erytroid precursors, 5% to 10% were monocyte-macrophages, 1 % to 15% were myeloblasts or promyelocytes, 0% to 25% were myelocytes or granulocytes, and 5% to 40% were lymphocytes. In 2 persons, 7% to 20% of cells were undifferentiated blasts.
LTBMCs were initiated with 0.2 to 5 X lo6 cells/flask (median, 0.9 x lo6 cells/flask). Adherent layers with "cobblestone" areas formed in cultures from 7 persons by day 15.
The number of nonadherent cells increased in all the cultures with an adherent layer by day 10 (Fig l) . Between days 5 and 15, nonadherent cells were predominantly monocytemacrophages, granulocytes, erythroblasts, and myelocytes (Table 2 ). In 8 experiments from 6 persons, production of nonadherent cells continued until cultures were terminated at day 35 to 40. In 2 experiments, cultures were continued until they stopped growing at day 62 and 74, respectively. From day 20, nonadherent cells were mostly monocytemacrophages and small round cells with scarce cytoplasm and dense chromatine.
In experiments in which the adherent layer was harvested on day 35 to 40, adherent cells were 4.5 f 3.1 X 106/flask (mean L 2 SD). These In experiments from 4 persons, addition ofgrowth factors to primary LTBMCs did not affect formation of adherent layer, production of nonadherent cells or CFU-GM, culture survival, or presence of cells able to initiate secondary LTBMCs at day 35.
DISCUSSION
We used LTBMCs to study hematopoietic cells in persons with Fanconi anemia and BM failure. Because BM samples contained few cells, cultures were initiated with numbers of cells far below ( 1% to 10%) those commonly used.' Nevertheless, apparently normal adherent layers formed in cultures from 7 of 8 persons and large numbers of differentiated myeloid cells were generated within 1 to 2 weeks. By day 35, the adherent layer of most cultures contained cells able to initiate secondary LTBMCs. However, growth of CFU-GM was impaired.
These data suggest that early hematopoietic precursors are present in the BM of persons with Fanconi anemia and BM failure. These cells are able to proliferate and differentiate in LTBMC but not in vivo and do not form colonies in the CFU-GM assay. The reason for these disparities is unknown. It is possible that in vitro conditions correct abnormalities present in vivo. For example, the culture medium may supply nutrients or growth factors absent in vivo. However, this does not explain the disparity between results of LTBMC and the CFU-GM assay, even when they were performed using the same culture medium. Also, addition of testosterone, hydrocortisone, or growth factors did not correct the deficit of CFU-GM ; similar data are reported for BFU-E and CFU-GEMM (Alter et a14 and B. Rotoli and R.
Notaro, personal communication).
Another possible explanation of the disparity between in vivo and in vitro hematopoiesis is the absence of toxins that operate in vivo but not in vitro. For example, some data suggest that Fanconi anemia cells are especially sensitive to oxygen-mediated damage." In this study, we avoided exposing cells to oxygen concentrations greater than 5%. However, a low O2 concentration is present in the BM in vivo." Also, LTBMC and CFU-GM were performed under similar conditions. An alternative explanation is that in vivo hematopoiesis is suppressed by mechanisms not operating in LTBMC. Considerable data suggest that leukemia is a multistep process and early phases of transformation are characterized by the expansion of a "preleukemia" clone that may retain the ability to In Fanconi anemia, this "preleukemia" clone (and possibly normal hematopoiesis) may be inhibited by specific or nonspecific mechanisms. This hypothesis is supported by clinical observations. For example, in a substantial proportion of persons with Fanconi anemia, the same cytogenetically abnormal clone was detected during BM failure and after developing leukemia.' Also, in some persons with Fanconi anemia and BM failure, development of clonal cytogenetic abnormalities was associated with transient hematopoietic recovery. Some of these persons eventually developed leukemia. ' Several of our observations support the notion that in Fanconi anemia, BM failure is related to leukemia transformation. For example, 2 of 6 persons with BM failure and less than 5% myeloblasts had clonal cytogenetic abnormalities similar to those reported in MDS and AML.I4 The disparity between capability to differentiate in LTBMC and results of C m G M may also mirror the disparity between ability to differentiate in vivo and impaired growth in clonogenic assays typical of persons with MDS.'5"8
Mechanisms that might suppress hematopoiesis in persons with Fanconi anemia and BM failure are unknown. Experimental data suggest that several phases of leukemia transformation including clonal expansion, inhibition of normal hematopoiesis, and possibly progression from "preleukemia" to leukemia, are regulated by complex mechanisms involving stromal, immune, and hematopoietic In preliminary experiments, we found that autologous blood mononuclear cells inhibit the growth of nonadherent cells in LTBMC (data not shown). Further studies of early hematopoietic precursors in Fanconi anemia are needed. These studies may explain early phases of leukemia transformation and cellular and humoral mechanisms regulating normal and leukemia hematopoiesis.
